Neoprobe Commences Lymphoseek Phase 3 Trial
 

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that a multicenter Phase 3 study of Lymphoseek® has been initiated in patients with either breast cancer or melanoma. The Phase 3 study will evaluate the efficacy of Lymphoseek to identify lymph nodes that may be predictive of determining whether a patient's cancer has spread into the lymphatic system.

More...